ocugen

FACT SHEET

DEVELOPING TRANSFORMATIVE THERAPIES TO TREAT THE WHOLE EYE

Company Highlights

- NASDAQ: OCGN
- Strong global IP
- Diversified Portfolio with Three Waves of Technological Innovation

	Indication		Prevalence (US)	Preclinical	Phase 1	Phase 2	Phase 3
OCULAR SURFACE DISEASE (small molecule)							
OCU300	oGVHD	Orphan US	63,000				
MODIFIER GENE THERAPY PLATFORM							
OCU400 *AAV-NR2E3*	*NR2E3* Mutation-Associated Retinal Degeneration	Orphan US	500-600				
	CEP290 Mutation-Associated Retinal Degeneration	Orphan US	2,500-3,000				
	RHO Mutation-Associated Re tinal Degeneration		10,400-12,700				
OCU410 *AAV-RORA*	Dry AMD		9-10M				
RETINAL DISEASES (novel biologic)							
OCU200 Tumstatin-Transferrin	Diabetic Macular Edema		745,000				
	Diabetic Retinopathy		7.7M				
	Wet AMD		1.1M				

Quick Facts

Ticker:
OCGN (NASDAQ)

Employees:
16 at 4/13/20

Cash & Investments:
$7.6M at 12/31/19

Location:
Malvern, PA

Shares Outstanding:
52.6M at 12/9/19

Strategic Partnership

Ocugen has entered into a strategic partnership with CanSino Biologics for the development of OCU400, Ocugen's first product candidate in its modifier gene therapy platform.

Collaboration paves a path for Ocugen to advance OCU400 into the clinic with significantly reduced capital and resources.

CanSinoBIO
September 2019

Seasoned Management Team

Shankar Musunuri, PhD, MBA
Chairman, CEO & Co-Founder

Dan Jorgensen, MD, MPH, MBA
Chief Medical Officer

Kelly Beck, MBA
VP, Investor Relations & Administration

Sanjay Subramanian, MBA
Chief Financial Officer

Rasappa Arumugham, PhD
Chief Scientific Officer

Vijay Tammara, PhD
SVP, Regulatory & Quality

OCU300: oGVHD

Proprietary nanoemulsion of brimonidine tartrate for the treatment of ocular redness and ocular discomfort in patients with oGVHD

- Phase 3, 84-day Randomized, Double-Masked, Placebo-Controlled Study
- 60 patients; 2:1 randomization
- Co-primary endpoints:
  - Symptom: Ocular discomfort based on Visual Analog Scale
  - Sign: Ocular redness based on Validated Bulbar Redness Score

OcuNanoE™ Drug Delivery System

Increases brimonidine in lacrimal gland and improves overall efficacy of OCU300



- OCU300 = Brimonidine (0.18%) OcuNanoE™
- Brimonidine = Commercial 0.2% solution
- Figure shows median, interquartile range, min/max fluorescein score
- **p<0.01

Modifier Gene Therapy

Introduce a functional gene to modify the expression of many genes, gene networks and reset homeostasis







30 days post-injection
^rd16 is another name for *CEP290* model

Mice Models represent different inherited retinal diseases

OCU200: Wet AMD, DME, DR

Tumstatin-Transferrin Fusion Protein offering benefits beyond Anti-VEGF

- First company focused on macromolecule (fusion protein) to target integrins for ocular diseases
- Integrin-targeting based approaches are actively explored in a variety of disease treatments, such as cancer, autoimmune, angiogenic and fibrotic treatments
- Selectively works on active endothelial cells; targeting element enhances effective concentration

Key Targeted Milestones

OCU300 ocular GVHD *(Phase 3 small molecule)*

- Mar 2020:Over 95% Planned Enrollment Achieved
- 2H2020: Topline Results Expected

OCU400 (*NR2E3*-AAV) Retinal Degenerative Diseases *(gene therapy)*

- 2020: Continue IND-Enabling Studies
- 2020: Initiated Tox Studies
- 2021: Target Phase 1/2a Clinical Trial

OCU200 Wet AMD, DME, DR *(novel biologic)*

- 2020-2021: Continue IND-Enabling Studies
- 2022 Target Phase 1/2a Clinical Trial

ocugen

For more information, please contact:

Kelly Beck, Vice President, Investor Relations
+1 484.328.4698 | kelly.beck@ocugen.com | **www.ocugen.com**